19.60

1.41% -0.28

Kiniksa Pharmaceuticals International Plc (KNSA)

Overview News Price History Option Chain Financials Discussions Forecast

Kiniksa Pharmaceuticals International Plc stock is traded at $19.60, with a volume of 271.24K. It is down -1.41% in the last 24 hours and down -0.91% over the past month. Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Previous Close:

$19.88

Open:

$20.1

24h Volume:

271.24K

Relative Volume:

0.80

Market Cap:

$1.42B

Revenue:

$384.10M

Net Income/Loss:

$-9.07M

P/E Ratio:

-140.00

EPS:

-0.14

Net Cash Flow:

$11.10M

1W Performance:

-2.15%

1M Performance:

-0.91%

6M Performance:

-26.32%

1Y Performance:

+11.17%

1-Day Range:

$19.55

$20.10

1-Week Range:

$19.55

$20.90

52-Week Range:

$16.56

$28.15

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name

Kiniksa Pharmaceuticals International Plc

Sector

Healthcare (1173)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

(781) 431-9100

Address

23 OLD BOND STREET, FLOOR 3, LONDON

Employee

297

Twitter

@kiniksa

Next Earnings Date

2024-10-29

Latest SEC Filings

KNSA's Discussions on Twitter

Compare KNSA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KNSA Kiniksa Pharmaceuticals International Plc	19.60	1.42B	384.10M	-9.07M	11.10M	-0.14
ZTS Zoetis Inc	170.90	77.10B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.47	42.82B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.39	42.45B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	17.73	20.09B	16.77B	-959.00M	1.37B	-0.85
NBIX Neurocrine Biosciences Inc	151.82	15.37B	2.24B	385.90M	440.10M	3.73

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-13-24	Initiated	Jefferies	Buy
May-03-24	Initiated	Wells Fargo	Overweight
Jun-29-20	Reiterated	BofA Securities	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Mar-11-19	Initiated	Barclays	Overweight
Dec-12-18	Reiterated	Wedbush	Outperform
Jun-19-18	Initiated	JMP Securities	Mkt Outperform

View All

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News

Jan 20, 2025

Kiniksa Pharmaceuticals Reports Strong 2024 Financial Results and Provides 2025 Revenue Guidance - Defense World

Jan 20, 2025

Jan 16, 2025

Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $255,413 - Investing.com India

Jan 16, 2025

Jan 14, 2025

Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.

Jan 14, 2025

Jan 13, 2025

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance - The Manila Times

Jan 13, 2025

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net - GlobeNewswire

Jan 13, 2025

Kiniksa's ARCALYST Soars 79% to $416M in 2024, Projects Strong 2025 Growth to $580M - StockTitan

Jan 13, 2025

Jan 06, 2025

Kiniksa Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 06, 2025

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Jan 06, 2025

Dec 18, 2024

Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $470k - Investing.com

Dec 18, 2024

Dec 11, 2024

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Fmr LLC - Defense World

Dec 11, 2024

Kiniksa Pharmaceuticals CFO sells shares worth $593,997 By Investing.com - Investing.com Nigeria

Dec 11, 2024

Dec 10, 2024

Kiniksa Pharmaceuticals CFO sells shares worth $593,997 - Investing.com

Dec 10, 2024

Dec 05, 2024

Kiniksa Pharmaceuticals CFO sells shares worth $323,008 By Investing.com - Investing.com Canada

Dec 05, 2024

Kiniksa Pharmaceuticals CFO sells shares worth $323,008 - Investing.com India

Dec 05, 2024

KNSA (Kiniksa Pharmaceuticals International) Treasury Stock : $0.0 Mil (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

Dec 02, 2024

Kiniksa Pharmaceuticals officer sells $194k in stock By Investing.com - Investing.com Nigeria

Dec 02, 2024

Kiniksa Pharmaceuticals officer sells $194k in stock - Investing.com India

Dec 02, 2024

Nov 30, 2024

Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com

Nov 30, 2024

Nov 26, 2024

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - Marketscreener.com

Nov 26, 2024

Nov 24, 2024

Principal Financial Group Inc. Sells 14,100 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World

Nov 24, 2024

Nov 20, 2024

Kiniksa Pharmaceuticals COO sells shares valued at $357,680 By Investing.com - Investing.com Nigeria

Nov 20, 2024

Kiniksa Pharmaceuticals COO sells shares valued at $357,680 - Investing.com India

Nov 20, 2024

Nov 15, 2024

HHLR Advisors, Ltd. Reduces Stake in Kiniksa Pharmaceuticals Int - GuruFocus.com

Nov 15, 2024

Nov 13, 2024

Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025? - Insider Monkey

Nov 13, 2024

Nov 12, 2024

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference 2024 | KNSA Stock News - StockTitan

Nov 12, 2024

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference - GlobeNewswire

Nov 12, 2024

10 Top Performing European Stocks Heading into 2025 - Insider Monkey

Nov 12, 2024

Nov 04, 2024